Don't miss a thing by getting the latest from the Manchester Evening News sent direct to your inbox A drug commonly prescribed to treat inflammatory bowel disease (IBD) may be linked to reduced coronavirus antibody response, a new study suggests.
According to the study, people who take infliximab may be more at risk of reinfection because the drug blunts the immune system to Covid-19 infection.
Now, researchers say careful monitoring of patients with IBD treated with infliximab, who have been vaccinated against the virus, will be needed to ensure they mount a strong enough antibody response to ward off the infection.
The Clarity study, which has been published in the Gut journal, recruited 6,935 patients with Crohn’s disease and ulcerative
Read more on manchestereveningnews.co.uk